260 related articles for article (PubMed ID: 21389099)
1. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
[TBL] [Abstract][Full Text] [Related]
7. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
Clin Cancer Res; 2008 Nov; 14(22):7358-66. PubMed ID: 19010851
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
Berkeley RA; Steele LP; Mulder AA; van den Wollenberg DJM; Kottke TJ; Thompson J; Coffey M; Hoeben RC; Vile RG; Melcher A; Ilett EJ
Cancer Immunol Res; 2018 Oct; 6(10):1161-1173. PubMed ID: 30209061
[TBL] [Abstract][Full Text] [Related]
9. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
10. Reovirus activates human dendritic cells to promote innate antitumor immunity.
Errington F; Steele L; Prestwich R; Harrington KJ; Pandha HS; Vidal L; de Bono J; Selby P; Coffey M; Vile R; Melcher A
J Immunol; 2008 May; 180(9):6018-26. PubMed ID: 18424722
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
[TBL] [Abstract][Full Text] [Related]
12. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
Babaei A; Soleimanjahi H; Soleimani M; Arefian E
Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.
Adair RA; Scott KJ; Fraser S; Errington-Mais F; Pandha H; Coffey M; Selby P; Cook GP; Vile R; Harrington KJ; Toogood G; Melcher AA
Int J Cancer; 2013 May; 132(10):2327-38. PubMed ID: 23114986
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
[TBL] [Abstract][Full Text] [Related]
17. Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus.
Kemp V; Hoeben RC; van den Wollenberg DJ
Viruses; 2015 Dec; 8(1):. PubMed ID: 26712782
[TBL] [Abstract][Full Text] [Related]
18. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R
Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
[TBL] [Abstract][Full Text] [Related]
20. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
